Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Using prostate-specific antigen to eliminate the staging radionuclide bone scan

C T Lee1, J E Oesterling

  • 1Michigan Prostate Institute, Ann Arbor, USA.

The Urologic Clinics of North America
|May 1, 1997
PubMed
Summary

Serum PSA testing can now help avoid unnecessary bone scans for prostate cancer staging. For asymptomatic patients with PSA ≤ 10 ng/mL, bone scans are not recommended, saving costs and time.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chinese family care partners of older adults in Canada have grit: A qualitative study.

Journal of advanced nursing·2023
Same author

Sarcopenic Obesity and its Prognostic Impact on Urological Cancers: A Systematic Review.

The Journal of urology·2021
Same author

Assessing the efficacy and acceptability of an internet-delivered intervention for resilience among college students: A pilot randomised control trial protocol.

Internet interventions·2019
Same author

Sampling considerations for a potential Zika virus urosurvey in New York City.

Epidemiology and infection·2018
Same author

Factors associated with food insecurity among older homeless adults: results from the HOPE HOME study.

Journal of public health (Oxford, England)·2018
Same author

Total and Candida - Specific IgE in Recurrent Vaginal Candidiasis.

Indian journal of dermatology, venereology and leprology·2017

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Urology

Background:

  • Radionuclide bone scans were historically essential for prostate cancer staging.
  • Lack of predictive tools for osseous metastases led to widespread bone scan use.

Purpose of the Study:

  • To evaluate the utility of serum Prostate-Specific Antigen (PSA) testing in refining the use of radionuclide bone scans for prostate cancer staging.
  • To identify specific patient subgroups where bone scans can be safely omitted.

Main Methods:

  • Review of clinical studies and authors' experience regarding PSA levels and osseous metastases.
  • Analysis of PSA's predictive value in conjunction with clinical stage and tumor grade.
  • Consideration of bone scan necessity in recurrent prostate cancer post-treatment.

Related Experiment Videos

Main Results:

  • Bone scans are unnecessary for asymptomatic, newly diagnosed prostate cancer patients with serum PSA ≤ 10 ng/mL.
  • Clinical stage and tumor grade do not significantly enhance PSA's predictive value for osseous metastases.
  • For recurrent prostate cancer post-prostatectomy, a serum PSA ≤ 2 ng/mL may obviate the need for bone scans.

Conclusions:

  • Serum PSA testing is a cost-effective tool to reduce unnecessary bone scans in prostate cancer management.
  • Optimizing bone scan utilization based on PSA levels can lead to significant healthcare cost savings.
  • Further research is ongoing to establish definitive PSA thresholds for restaging after radiation therapy or watchful waiting.